ALKERMES | ALKS - Gross Profit On Sales


ALKERMES reported $303.36M in Gross Profit on Sales for its fiscal quarter ending in September of 2026.





Gross Profit On Sales Change Date
AbbVie USD 14.8B 411M Sep/2026
Acadia Pharmaceuticals USD 307.2M 27.56M Sep/2026
ALKERMES USD 303.36M 71.95M Sep/2026
Amgen USD 8.46B 1.22B Sep/2026
Biogen USD 2.25B 127.8M Sep/2026
BioMarin Pharmaceutical USD 719.77M 6.35M Sep/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Coherus Biosciences USD 8.7M 853K Dec/2025
Eli Lilly USD 20.59B 886M Sep/2026
Gilead Sciences USD 6.73B 74M Sep/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Ionis Pharmaceuticals USD 240M 25M Sep/2026
J&J USD 18.55B 6M Sep/2026
Merck USD 12.21B 121M Jun/2026
Minerva Neurosciences -4.27M 26.79M Dec/2024
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 1.06B 125.3M Sep/2026
Otsuka Holdings JPY 512.64B 2.41B Sep/2026
Pfizer USD 3.24B 3.49B Sep/2026
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Vertex Pharmaceuticals USD 2.94B 99.9M Sep/2026